Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript

Operator

Hello, and welcome to The Platform Behind the Pipeline, Cellectar Biosciences’ educational webinar. [Operator Instructions] Also as a reminder, this conference is being recorded today.

Anne Marie, you may begin.

Anne Marie Fields
Precision AQ

Thank you, operator. This is Anne Marie Fields, Managing Director at Precision AQ. Good morning, and welcome to Cellectar Biosciences’ educational webinar on The Platform Behind the Pipeline. Joining us today from Cellectar are Jim Caruso, President and CEO, who will provide opening remarks, and Jarrod Longcor, Chief Operating Officer, who will review the scientific and clinical rationale behind the company’s phospholipid ether platform underlying its promising clinical development pipeline of radiopharmaceuticals.

I want to remind participants that the information discussed on today’s webinar is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. I caution listeners that management will be making forward-looking statements. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business. These forward-looking statements are qualified in their entirety by these cautionary statements and in the company’s SEC filings. The content of this webinar contains time-sensitive information that is accurate only as of the date of this live broadcast, August 18, 2026. The company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this webinar.

As a